This review summarizes the development of new anticoagulant drugs for the prevention and treatment of venous and arterial thromboembolism, addressing the limitations of traditional therapies.
Answers are grounded in this paper and cite their sources.
Informs research on novel anticoagulants; does not yet warrant changes in thromboembolism management.
The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing. British Journal of Pharmacology (2005) 144 , 1017–1028. doi: 10.1038/sj.bjp.0706153
No takes yet. Share an insight, caveat, or question.
Bates et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: